Non-small cell lung cancer and melanoma are at the forefront of molecular diagnostics, with a variety of treatments targeting molecular alterations defining specific cancer subtypes (e.g., BRAF, EGFR, ALK alterations). This evidence concerns the gene BRAF and melanoma.